Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Outlook
2023

Annual Industry Ranking And Forecast

Medtech 100: Why Patient-Centered Care Has To Change

Going the last mile is taking longer than it should

Executive Summary

A typical word cloud for discussions around patient-centered care would feature: business model, digital health, financing, PPP, resources, data sharing, staffing and escalation of costs. But so many other words are missing, which is why patient-centricity risks getting stuck in its current incomplete form. What are medtechs to do?

You may also be interested in...



The Current Growth Drivers For Medtech In The Asia-Pacific Region

The eighth annual MedTech Forum from APACMed chose Patient Futures as its 2022 theme. New chairman John Collings described to In Vivo how the local industry is seeking to both protect data and build trust with patients.

UK Updates Guidance To Reflect EU Medtech Extensions - Pledges Focus On Agility, Innovation

The EU’s decision to extend the Medical Device Regulation transition periods for legacy medical device directives products will be mirrored in the UK, which also continues to evolve its post-Brexit medtech regulatory system.

Switzerland’s Swift Reaction To MDR’s Extended Transitions Keeps EU Equivalency

The medtech regulatory authorities in Switzerland have pledged to follow the EU’s lead in granting extended transition periods for legacy devices under the MDR.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT147446

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel